S-1/A: Revelation Biosciences Eyes $5 Million in Best Efforts Public Offering

Revelation Biosciences launches a best efforts public offering aiming to raise up to $5 million through shares, pre-funded warrants, and common stock warrants.

Summary

• Revelation Biosciences is undertaking a best efforts public offering to raise capital.
• The offering includes up to 1,949,317 shares of common stock.
• It also includes pre-funded warrants to purchase up to 1,949,317 shares of common stock.
• Additionally, Class H common stock warrants to purchase up to 7,797,268 shares of common stock are part of the offering.
• The assumed combined public offering price is $2.565 per share of common stock and accompanying common stock warrants.
• Pre-funded warrants are offered to purchasers whose ownership would exceed 4.99% (or 9.99%) of outstanding common stock after the offering.
• Each pre-funded warrant's purchase price equals the per-share public offering price less $0.0001, with an exercise price of $0.0001 per share.
• The offering will terminate on the earlier of the date securities purchase agreements are entered into or June 4, 2025.
• Net proceeds are estimated at $4,335,407, to be used for product development, clinical drug supply manufacture, preclinical work, and general corporate purposes.
• Roth Capital Partners, LLC is the exclusive placement agent.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the company is raising capital, which is generally positive, the offering is on a best efforts basis and involves dilution for existing shareholders. The company also has a limited operating history and has incurred net losses since its inception.

Positives

• The offering aims to provide capital for the further development of Revelation Biosciences' product candidates.
• Funds will support the completion of an ongoing Phase 1b clinical study.
• Funds will support the manufacture of clinical drug supply.
• Funds will support additional preclinical work for multiple indications.
• Funds will support the continued development of other products and therapies.
• Funds will support working capital and general corporate purposes.

Negatives

• The offering is on a best efforts basis, so the company may not raise the full amount.
• The company has broad discretion in the use of the net proceeds.
• Investors will experience immediate and substantial dilution in the net tangible book value of shares.
• The common stock warrants are not exercisable until stockholder approval is obtained.
• The common stock warrants may not have any value.

Risks

• The company has a limited operating history and has incurred net losses since its inception.
• The company may not be able to raise additional funding on acceptable terms, or at all.
• The company relies on third parties to conduct certain elements of its preclinical and clinical studies and perform other tasks for us.
• The company may infringe the intellectual property rights of others, which could increase our costs and delay or prevent our development efforts.
• The company's common stock price may be volatile and as a result you could lose all or part of your investment.
• The common stock warrants are not exercisable until Stockholder Approval and may not have any value.
• This offering may cause the price of our common stock to decline and fall below the minimum bid price requirement required by the Nasdaq Listing Rules, which could result in our Common Stock being delisted from The Nasdaq Capital Market.

Future Outlook

The company intends to use the net proceeds from this offering to further the development of its product candidates, including the completion of its ongoing Phase 1b clinical study, the manufacture of clinical drug supply, additional preclinical work for multiple indications, continue to develop other products and therapies, and fund working capital and general corporate purposes.

Industry Context

This announcement is typical for clinical-stage biopharmaceutical companies seeking funding to advance their drug development programs. The company is focusing on rebalancing inflammation to optimize health using its proprietary formulation Gemini. The company is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelations proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established Toll-like receptor 4 (TLR4) agonist that can stimulate the human bodys innate immune response to prevent and treat disease.

Comparison to Industry Standards

• The decision to conduct a best efforts offering is common among smaller biotech companies that may not have the track record or market capitalization to attract a traditional underwritten offering.
• The use of warrants as part of the offering is a common strategy to attract investors, particularly in the biotech sector, where the risk profile can be high.
• The focus on clinical-stage assets and the need for further funding is typical for companies in this sector, as drug development is a capital-intensive process.
• The company's strategy of developing a pipeline of potential high-value products based on Gemini is similar to other companies in the industry.

Stakeholder Impact

• Shareholders will experience dilution as a result of the offering.
• The company's employees may benefit from the increased funding for product development.
• The company's customers may benefit from the development of new products and therapies.

Next Steps

• The company will deliver the securities being issued to the investors upon receipt of investor funds.
• The company will apply to list or quote all of the Shares and Warrant Shares on such Trading Market and promptly secure the listing of all of the Shares and Warrant Shares on such Trading Market.
• The company will hold an annual or special meeting of stockholders on or prior to the date that is sixty (60) days following the Closing Date for the purpose of obtaining Stockholder Approval.

Key Dates

Keywords

public offering, common stock, warrants, pre-funded warrants, Revelation Biosciences, capital raise, clinical development, biopharmaceutical, Roth Capital Partners, securities